The global antifungal drug market is anticipated to grow at a significant CAGR during the forecast period (2022-2028). The fungal infection in the body is caused due to unhygienic and unclean environments wherein fungal agents thrive. These agents multiply by spreading spores that subsequently lead to infection on the skin (superficial) or when inhaled (systemic)-fungal infections. The fungal infection leads to candidiasis, fungal pneumonia, mucormycosis, and other diseases. These infections are mostly non-lethal but can result in death in rare cases. Antifungal drugs are used to detect and treat fungal pathogens from the body with minimal to no toxic side effects to the body. The major factor for the growth of the market during the include the rising number of patients suffering from hygiene-related diseases in developing countries and developed countries. According to the National Center for Biotechnology Information (NCBI), fungal diseases affect over a billion people every year. Furthermore, the market is driven by the increasing immunity deficient, geriatric population, and rise in exposure to infectious agents due to environmental factors such as pollution. 

Some key players operating in the market include GlaxoSmithKline plc, Pfizer Inc., and Abbott Laboratories, among others.  The market players are eyeing on strengthening their position in the market by adopting various strategies such as mergers and acquisitions, partnerships and collaborations, and new product launches. For instance, in July 2021, Cadila Pharmaceuticals has launched a new triazole antifungal drug Posaconazole for the effective treatment against a wide range of invasive fungal diseases. Additionally, in May 2021, MSN Laboratories has launched a new antifungal drug Posaconazole used in the treatment of mucormycosis or Black Fungus.

Market Coverage

• The market number available for – 2020-2027
• Base year- 2020
• Forecast period- 2022-2028

Segment Covered- 

• By Drug Type

Regions covered-

• North America
• Europe
• Asia-Pacific
• Rest of the World

Competitive Landscape:  GlaxoSmithKline plc, Pfizer Inc., and Abbott Laboratories, among others.

Key questions addressed by the report

• What is the market growth rate?
• Which segment and region dominate the market in the base year?
• Which segment and region will project the fastest growth in the market?
• How COVID-19 impacted the market?

o Deviation from the pre-COVID-19 forecast

o Most affected region and segment

• Who is the leader in the market?
• How are players addressing challenges to sustain growth?
• Where is the investment opportunity?

Global Antifungal Drug Market Report by Segment

By Drug Type

• Echinocandins
• Azoles
• Polyenes
• Allylamines
• Others

By Indication

• Candidiasis
• Aspergillosis
• Dermatophytosis
• Others

Global Antifungal Drug Market Report by Region

North America       

• US
• Canada

Europe

• Germany
• UK
• France
• Spain
• Italy
• Rest of Europe

Asia-Pacific    

• China
• Japan
• India
• Rest of Asia-Pacific

Rest of the World

• Latin America
• Middle East and Africa